Why Human Germline Editing Might Never Be Legal in the U.S.
By Jennifer M. Gumer,
The Hastings Center
| 08. 09. 2019
What would it take for the first case of germline editing to proceed under applicable U.S. law and ethical standards?
A Russian scientist recently announced his intention to use the gene-editing tool CRISPR to edit and implant human embryos—a revelation that met with international outcry similar to the condemnation of the Chinese scientist He Jiankui last year when he announced that he had created the first gene-edited babies. Jiankui’s actions — deemed unethical for several reasons – led to a call for a moratorium on editing human germline cells (sperm, eggs, or embryos) to produce genetically modified babies.
Even the signatories of the moratorium, however, suggest that CRISPR might one day be safe enough for ethical, clinical use on the germline. What would it take for the first case of germline editing to proceed under applicable U.S. law and ethical standards?
Germline editing would be regulated as a gene therapy by the Food and Drug Administration. To comply with the relevant regulations, germline editing must undergo clinical testing to demonstrate safety and efficacy and win FDA approval before coming to market. Currently, federal law prevents the FDA from reviewing or approving any application involving manipulated human embryos. However, if...
Related Articles
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...